196 related articles for article (PubMed ID: 31441963)
1. Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania.
Scheiber AL; Barton DK; Khoury BM; Marini JC; Swiderski DL; Caird MS; Kozloff KM
J Bone Miner Res; 2019 Dec; 34(12):2301-2310. PubMed ID: 31441963
[TBL] [Abstract][Full Text] [Related]
2. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
3. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
[TBL] [Abstract][Full Text] [Related]
7. Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.
Sinder BP; Lloyd WR; Salemi JD; Marini JC; Caird MS; Morris MD; Kozloff KM
Bone; 2016 Mar; 84():222-229. PubMed ID: 26769006
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
[TBL] [Abstract][Full Text] [Related]
9. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.
Perosky JE; Khoury BM; Jenks TN; Ward FS; Cortright K; Meyer B; Barton DK; Sinder BP; Marini JC; Caird MS; Kozloff KM
Bone; 2016 Dec; 93():79-85. PubMed ID: 27641475
[TBL] [Abstract][Full Text] [Related]
10. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
[TBL] [Abstract][Full Text] [Related]
11. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
[TBL] [Abstract][Full Text] [Related]
13. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
15. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse.
Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C
Front Genet; 2021; 12():705505. PubMed ID: 34447412
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFβ inducible early gene-1 knockout female mice.
Gingery A; Subramaniam M; Pitel KS; Li X; Ke HZ; Turner RT; Iwaniec UT; Hawse JR
J Cell Physiol; 2020 Jul; 235(7-8):5679-5688. PubMed ID: 31975377
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin antibody stimulates bone regeneration after experimental periodontitis.
Taut AD; Jin Q; Chung JH; Galindo-Moreno P; Yi ES; Sugai JV; Ke HZ; Liu M; Giannobile WV
J Bone Miner Res; 2013 Nov; 28(11):2347-56. PubMed ID: 23712325
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
[TBL] [Abstract][Full Text] [Related]
20. A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.
Surowiec RK; Battle LF; Ward FS; Schlecht SH; Khoury BM; Robbins C; Wojtys EM; Caird MS; Kozloff KM
Bone; 2020 Jan; 130():115118. PubMed ID: 31678490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
